Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care

In this online CME-certified program centered around a dynamic CCO symposium in Orlando, experts discuss recent advances in the management of essential thrombocythemia, polycythemia vera, and myelofibrosis. Watch the on-demand Webcast and download the slides from the symposium and read expert commentaries on current and emerging therapeutic strategies for patients with MPNs.
Srdan Verstovsek, MD, PhD

ClinicalThought

Outcomes are poor for patients with myelofibrosis who discontinue ruxolitinib due to loss of response or intolerance. In this commentary, I offer my thoughts on the best treatment options for these patients.

Srdan Verstovsek, MD, PhD Released: October 7, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Celgene Corporation
CTI Biopharma
Geron

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?